SCHEMBL5887069

SCHEMBL5887069

COc1ccc(C2=C(Cl)C=CC[CH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ESR2 Q92731 1/20 0.37
APP P05067 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MAPK1 P28482 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
NPC1 O15118 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6047592 0.83 ALOX5 (0.44) MAPK1MAPTMEN1KMT2ANPC1
SCHEMBL5886818 0.81 CA12 (0.39) CA12CA1CA2CA7CA9
SCHEMBL4811178 0.80 HPGD (0.34) KDM4ETDP1MAPTMEN1KMT2A
SCHEMBL6047581 0.78 ACHE (0.50) CA12CA1CA2CA7CA9
SCHEMBL6047623 0.78 ALDH1A1 (0.47) KDM4ETDP1MAPTMEN1KMT2A
SCHEMBL6047658 0.77 NPC1 (0.41) APPKDM4EMAPK1TDP1MAPT
SCHEMBL4808801 0.77 APP (0.38) CA12CA1CA2CA7CA9
SCHEMBL5887251 0.71 BACE1 (0.41) CA12CA1CA2CA7CA9
SCHEMBL5887556 0.68 ALOX5 (0.40) MAPK1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL5887097 0.68 ALOX5 (0.40) KDM4EMAPK1TDP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R CA12 4319/4885CA1 2466/4885CA2 3355/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R CA12 3395/4885CA1 1720/4885CA2 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.